Lionel Pochet is a Professor at the University of Namur, active in drug design, thrombosis research, and analytical chemistry. His work focuses on coagulation cascade inhibitors and fragment-based drug discovery. Namur Medicine & Drug Innovation Center Namur Thrombosis and Hemostasis Center Namur Research Institute for Life Sciences His research spans coumarin derivatives , FXIIa inhibition , and covalent probes for protein interactions. Recent projects include targeted covalent inhibitors for Mycobacterium tuberculosis and lactate dehydrogenase. Key publications highlight pharmacological evaluation , mass spectrometry , and structural chemistry applications in drug discovery. Awards and grants are not explicitly mentioned in the provided text.
Jean-Michel Dogné is a full Professor at the Faculty of Medicine, University of Namur, where he leads research in clinical pharmacology and toxicology. He is affiliated with several key research centers including the Namur Medicine & Drug Innovation Center, the Namur Thrombosis and Hemostasis Center, and the Namur Nanosafety Center. His work is integral to the Namur Research Institute for Life Sciences and he actively contributes to EU-level pharmacovigilance through his role in the EMA's PRAC committee. Education: Doctor of Pharmacy, Université de Liège (2000), Thesis: Drug design and development His research focuses on anticoagulant therapy, thrombosis, drug safety, and personalized medicine , with strong emphasis on clinical applications in cancer and infectious diseases. He has led major projects such as COVILAB (on COVID-19) and studies on BCR-ABL inhibitors in leukemia. His work often involves systematic reviews, meta-analyses, and biomarker discovery, contributing to evidence-based medicine. The 15 most recent publications reflect a sustained focus on thrombosis in oncology, pharmacovigilance, anticoagulants, and pandemic research , with increasing integration of regulatory science and model-informed drug development. His work spans clinical trials, laboratory investigations, crystallography, and public health policy , demonstrating a multidisciplinary approach to pharmaceutical innovation. Scientific Awards: Prix Léo Pharma Cancer & Thrombosis (2017) Jean-Michel Dogné has supervised over 40 students and researchers, contributing significantly to training the next generation of clinical pharmacologists. He has secured numerous national and international grants, particularly in the areas of drug safety and thrombosis. His collaborative network is extensive, involving institutions across Europe and participation in EU-level regulatory bodies. He is a key member of the Clinical Pharmacology Research Group and leads major initiatives such as the MP-EMA project. His team operates within state-of-the-art facilities at the University of Namur, focusing on translational research from bench to bedside.
Pierre Bulpa is an active researcher with expertise in hematology, pulmonary medicine, and critical care, focusing on thrombotic complications in severe COVID-19 and lung transplantation. His work intersects with the UN Sustainable Development Goals related to health and well-being (SDG 3) and innovation (SDG 9). Collaborations span international institutions, particularly in hemostasis and respiratory disease research. Key research areas: Thrombosis in critically ill patients, lung transplantation, methadone's role in transplant outcomes, and diagnostic algorithms for pulmonary aspergillosis. Recent publications (2020–2023) emphasize longitudinal hemostasis disturbances in COVID-19, validated biomarkers, and data-driven clinical insights. Collaborations include multidisciplinary teams across Belgium and France, with contributions to clinical guidelines.
Jonathan Douxfils is a Professor at the University of Namur, affiliated with the Namur Research Institute for Life Sciences and the Thrombosis and Hemostasis Center. His expertise lies in pharmacology, thrombosis, and anticoagulant therapies. He holds a Pharm.D. and Ph.D. from the University of Namur and a Master of Pharmacy from Université Catholique de Louvain. Key roles include CEO of Qualiblood, Co-Chairman of the International Society on Thrombosis and Hemostasis's SSC Control of Anticoagulation, and Pharmacovigilance Expert at the Federal Agency of Medicines and Health Products. His research focuses on anticoagulant safety, thrombosis risk assessment, and innovative diagnostic tools like the DOAC Dipstick. Notable awards include the Alfers Prize 2022, Eberhard F. Mammen Young Investigator Award 2019, and multiple recognition in hemostasis research. He leads projects such as NucleoGlio (glioblastoma diagnostics) and GT4HEALTH (gene therapy research). He has supervised 19 thesis works and contributed to over 436 research outputs. His work aligns with UN SDGs in health and innovation.
Isabelle Michaux is a researcher at Catholic University of Louvain's School of Medicine, Department of Anesthesiology and Critical Care, with significant contributions to hemostasis research and critical care medicine. Her work spans thrombosis monitoring in critical illness, cardiac surgery complications, and infectious disease management, particularly during the COVID-19 pandemic. Her primary research focuses on hemostasis disturbances in critical care settings , with expertise in thrombosis biomarkers (D-dimer, fibrin monomer), coagulopathy in viral infections, and blood product optimization for surgical patients. Recent work examines vasopressor effects on renal oxygenation and left ventricular thrombus formation in cardiomyopathies. Her research integrates clinical observations with laboratory hemostasis parameters to improve outcomes in critically ill patients. Analysis of her publication trends reveals a strong emphasis on translational hemostasis research , evolving from COVID-19 coagulopathy studies (2020-2021) to broader surgical complication prevention (2023-2024). Key thematic areas include thrombosis prediction in critical illness, antimicrobial stewardship in viral infections, and cardiac complications in transplantation medicine. Her scholarly impact is reflected in a Scopus h-index of 74 with significant citation metrics, including 38 citations for her seminal work on COVID-19 hemostasis disturbances. Her research has been referenced in clinical guidelines and garnered attention across X (formerly Twitter) with over 100 posts and 148 Mendeley readers. Dr. Michaux maintains active collaborations across European institutions, particularly with University Hospital Center teams. Her current research network focuses on surgical complication prevention, with projects spanning cardiac surgery blood management, lung transplantation outcomes, and critical care nephrology. She contributes to antimicrobial stewardship through surveillance studies of viral infections and hospital epidemiology.
Julie Vassart is a Researcher at the University of Namur's Namur Research Institute for Life Sciences and Clinical Pharmacology Research Group. Her work focuses on anticoagulant therapy monitoring, particularly Direct Oral Anticoagulants (DOACs), with active involvement in multiple national and international projects including the BIOCOAG initiative and FXI(a) inhibitor management studies. Her educational background includes: Master in Pharmaceutical Sciences (2022), University of Namur Dr. Vassart's research centers on developing and validating rapid diagnostic tools for anticoagulant monitoring, with emphasis on DOAC Dipstick accuracy in perioperative settings and novel anticoagulants like asundexian. Her work bridges clinical pharmacology, hematology, and analytical chemistry to improve patient safety during anticoagulation therapy. Current projects investigate intrinsic pathway inhibitors and real-time anticoagulant level assessment. Recent publications demonstrate a clear trend toward point-of-care anticoagulant monitoring solutions, with significant contributions to expert consensus guidelines for DOAC testing. Her research spans method validation against gold-standard techniques (UHPLC-MS/MS), clinical applicability in surgical contexts, and novel anticoagulant impact on coagulation pathways. Scientific recognition includes: Travel award (2024) for conference participation She actively contributes to 3 major research projects: the long-running BIOCOAG project (since 2011) assessing anticoagulation control biology, the FXI(a) inhibitors PhD project (2022–present), and collaborative studies with international consortia. Her work is presented regularly at premier hemostasis conferences including EuroThrombosis and the Belgian Society on Thrombosis and Haemostasis meetings. Dr. Vassart operates within the Clinical Pharmacology Research Group at the Namur Thrombosis and Hemostasis Center (NTHC), which specializes in anticoagulant pharmacology, coagulation assay development, and thrombosis risk assessment using advanced laboratory techniques.
Laure Morimont is a Researcher at the Namur Research Institute for Life Sciences, part of the Clinical Pharmacology and Toxicology Research Unit. Her research focuses on thrombosis, coagulation disorders, and the effects of hormonal therapies and contraceptives on blood clotting. She contributes to projects like the COVILAB initiative on SARS-CoV-2 and the HIC Project evaluating hormone-induced coagulopathy. Morimont has received awards including the 2021 Best Oral Presentation and the 2020 Belgian MedTech Program recognition. Her work spans clinical pharmacology, venous thromboembolism risk assessment, and coagulation testing innovations. Key Projects: Clinical Pharmacology Research Group (2022–present) COVILAB: SARS-CoV-2 investigations (2020–present) HIC Project: Hormone-induced coagulopathy evaluation (2019–2023) Research Interests: Thrombin generation and anticoagulant efficacy Risk assessment of hormonal therapies Coagulopathy in pregnancy and cancer patients Her articles emphasize anticoagulant pharmacodynamics, contraceptive safety, and clinical diagnostic tools like the DOAC Dipstick. Morimont actively collaborates internationally and presents at conferences such as the ISTH Congress. She also leads studies on thrombosis prediction models and coagulation assay standardization.
Kathleen Freson is a Professor at the Faculty of Medicine , KU Leuven. She serves as Director of the Biomedical Sciences Doctoral School and Head of the Center for Molecular and Vascular Biology . Her research focuses on genetic hemostasis disorders , thrombophilia , and inherited platelet defects , with emphasis on genotype-phenotype correlations and omics-based disease modeling . Key projects: Multigene panels for thrombophilia, whole-genome sequencing for platelet disorders, functional assessment of anticoagulant variants Her recent publications address venous thromboembolism epidemiology , neurodevelopmental disorders linked to snRNA mutations , and clinical applications of genetic sequencing in bleeding diseases . She collaborates with institutions like the KU Leuven Institute for Rare Diseases and contributes to ISTH nomenclature guidelines .
Marie Didembourg is a researcher at the University of Namur, affiliated with the Department of Clinical Pharmacology and Toxicology and the Namur Thrombosis and Hemostasis Center (NTHC). Her work contributes to the UN Sustainable Development Goals, particularly in the area of Good Health and Well-being. She focuses on the interplay between hormonal therapies and coagulation disorders, with a strong emphasis on thrombin, estrogens, and anticoagulant pharmacodynamics. Research Interests: Hormone-induced coagulopathy, thrombin interactions, venous thromboembolism, neutralizing antibodies in pregnancy, and comparative evaluation of hormonal therapies. Recent Activities: Presented at the 31st BTSH, ISTH 2024, and the 21st World Congress of the International Society of Gynecological Endocrinology. Media Contributions: Co-authored press releases on natural estrogen-based contraceptives and SARS-CoV-2 antibody responses during pregnancy.
Romain Siriez is a Researcher at the University of Namur, affiliated with the Namur Thrombosis & Hemostasis Center (NTHC) and Namur Research Institute for Life Sciences (NARILIS) . His work focuses on anticoagulant therapy monitoring , thrombosis diagnostics , and pharmacokinetics of direct oral anticoagulants (DOACs) , particularly edoxaban. Education: Doctor of Biomedical and Pharmaceutical Sciences (2022, University of Namur). Research interests include optimizing coagulation assays for DOAC-treated patients, assessing activated protein C (APC) resistance , and developing point-of-care diagnostic tools in emergency medicine. His contributions address challenges in plasmatic evaluation of Factor Xa inhibitors , aligning with UN Sustainable Development Goal 3 (Good Health and Well-being). Selected articles highlight advancements in FibWave technology for thrombophilia diagnostics and chromogenic assays for edoxaban metabolite quantification. These works emphasize diagnostic accuracy , anticoagulant performance , and laboratory hematology . Awards: MT180 2018 Prize (Ulg-UNamur) Collaborations include partnerships with the NTHC and international symposiums on laboratory hematology innovations. His research is referenced in clinical guidelines and disseminated through conferences like the European Congress on Thrombosis and Haemostasis (2018) and XXXIInd ISLH Symposium (2019).
Bernard Chatelain is a prominent researcher affiliated with the Namur Thrombosis and Hemostasis Center and the Catholic University of Louvain (UCLouvain), specializing in thrombosis, hemostasis, and anticoagulant therapies. His work bridges clinical laboratory practices with research on fibrinolytic systems, microparticles in thrombotic diseases, and thrombotic risk management during pandemics like COVID-19. Recent Research Focus: Development of integrative assays for fibrinolytic system phenotyping, optimization of coagulation testing protocols, and analysis of anticoagulant impacts on platelet function. Collaborations: Active partnerships with institutions like UCLouvain, Université de Namur, and international hemostasis laboratories. His scientific contributions include over 146 research outputs, with recent publications addressing: Standardization of prothrombin time measurements using novel thromboplastin reagents. Time-sensitive variables in platelet testing accuracy. Thrombotic risk mitigation frameworks during global health crises. Chatelain’s work has informed clinical guidelines and been referenced in policy documents, highlighting its translational significance.
Hugues Jacqmin holds a Doctorate in Biomedical and Pharmaceutical Sciences from the Faculty of Medicine at the University of Namur, Belgium. His research focuses on hematology and thrombosis, particularly in anticoagulant therapy, platelet function analysis, and blood coagulation disorders. Research interests include: Standardization of hemostasis testing Impact of anticoagulation on diagnostic accuracy Thrombotic risks in severe diseases like COVID-19 Platelet testing methodologies Recent work involves evaluating thromboplastin reagents, analyzing plasma variability in lupus anticoagulant testing, and studying prothrombotic states in critical care patients. Collaborations span clinical and biomedical fields, with co-authors from hematology, pharmacy, and critical care disciplines.
Bernard Masereel is a senior academic and research leader at the University of Namur, affiliated with the Namur Research Institute for Life Sciences and the Unite de recherche en pharmacologie et toxicologie clinique. He is a key member of the Clinical Pharmacology Research Group and contributes to the NAmur MEdicine & Drug Innovation Center and the Namur Thrombosis and Hemostasis Center. His work is internationally recognized, with over 379 research outputs and an h-index of 42. His research focuses on medicinal chemistry and pharmacological innovation, particularly in cancer therapy and anticoagulant development. He specializes in the design and synthesis of beta-carboline and boronic compounds for applications such as boron neutron capture therapy and the inhibition of serine proteases involved in thrombosis. His fingerprint includes core topics like synthesis, cancer, receptors, and inhibition, reflecting a strong commitment to drug discovery and evaluation. His recent publications from 2017 to 2022 demonstrate a consistent focus on anti-cancer compounds, proteomic investigations, and analytical methodologies in pharmaceutical quality control. These works highlight interdisciplinary approaches combining organic synthesis, biochemical assays, and clinical applications. Bernard Masereel has supervised numerous research projects and students, contributing significantly to training and innovation in pharmaceutical sciences. He has been involved in key initiatives such as the Télévie and BNCT projects, demonstrating leadership in translational research. He is active in organizing and participating in scientific conferences, including the Franco-Belgian Medicinal Chemistry Days and workshops on anticoagulants and drug design. His work supports Sustainable Development Goals related to health and innovation.
Dr. Adeline WANNEZ is a researcher at the Faculty of Medicine, University of Namur, specializing in thrombosis mechanisms and extracellular vesicle biology. Her work bridges biomedical science with clinical hematology. Doctorate in Biomedical and Pharmaceutical Sciences (2018) Master in Biomedicine (2014) Research Interests: Focuses on blood coagulation risks , extracellular vesicle dynamics , and hematological malignancies . Key methodologies include flow cytometry and clot-based assays . Her publications (2016-2020) cover thrombosis in leukemia patients microRNA biomarkers in lymphoma procoagulant activity of blood products flow cytometry protocols for vesicle analysis
Jonathan Evrard is a researcher affiliated with the University of Namur , specializing in Clinical Pharmacology . His work primarily focuses on anticoagulant therapy, thrombosis, and hemostasis, with a strong emphasis on developing and evaluating analytical tools like FibWave for coagulation assessment. Key projects : CAF (clot formation assessment), BIOCOAG (biological anticoagulation control), POC-FibWave (fibrin clot automation), HIC (hormone-induced coagulopathy). Research interests : Anticoagulant pharmacology, clot waveform analysis, thrombin generation, fibrinolysis, and hormonal impacts on coagulation. Collaborations : Works closely with Prof. Jean-Michel Dogné, Prof. Jonathan Douxfils, and the Namur Thrombosis & Hemostasis Center (NTHC).
